(Q28295125)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23881605%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

title

Targeted opioid receptor antagonists in the treatment of alcohol use disorders (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23881605%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

0 references

0 references

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23881605%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

author name string

Albert J Arias

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23881605%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

language of work or name

English

0 references

publication date

1 October 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23881605%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23881605%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

volume

27

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23881605%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

issue

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23881605%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

page(s)

777-787

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23881605%20AND%20SRC:MED&resulttype=core&format=json

An evaluation of mu-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) study

5 March 2020

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4600601

A prospective study of risk drinking: at risk for what?

20 March 2017

2 references

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4600601

20 March 2017

https://api.crossref.org/works/10.1007%2FS40263-013-0096-4

Nalmefene induced elevation in serum prolactin in normal human volunteers: partial kappa opioid agonist activity?

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4600601

Single-nucleotide polymorphism in the human mu opioid receptor gene alters beta-endorphin binding and activity: possible implications for opiate addiction

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4600601

Variation in OPRM1 moderates the effect of desire to drink on subsequent drinking and its attenuation by naltrexone treatment

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4600601

The relationship between naloxone-induced cortisol and mu opioid receptor availability in mesolimbic structures is disrupted in alcohol dependent subjects.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4600601

Pharmacogenetically driven treatments for alcoholism: are we there yet?

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4600601

The kappa opioid receptor antagonist JDTic attenuates alcohol seeking and withdrawal anxiety

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4600601

The road to a world health organization global strategy for reducing the harmful use of alcohol.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4600601

κ-opioid receptors are implicated in the increased potency of intra-accumbens nalmefene in ethanol-dependent rats

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4600601

Gender differences in alcohol treatment: an analysis of outcome from the COMBINE study

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4600601

In vivo characterization of the opioid antagonist nalmefene in mice

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4600601

Targeted naltrexone for problem drinkers

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4600601

Sweet liking phenotype, alcohol craving and response to naltrexone treatment in alcohol dependence

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4600601

Do patients with alcohol dependence respond to placebo? Results from the COMBINE Study

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4600601

Effects of opioid receptor gene variation on targeted nalmefene treatment in heavy drinkers

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4600601

Naltrexone and cognitive behavioral therapy for the treatment of alcohol dependence: do sex differences exist?

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4600601

The therapeutic alliance in medical-based interventions impacts outcome in treating alcohol dependence

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4600601

Update on neuropharmacological treatments for alcoholism: scientific basis and clinical findings

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4600601

Targeted nalmefene with simple medical management in the treatment of heavy drinkers: a randomized double-blind placebo-controlled multicenter study

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4600601

New insights into the efficacy of naltrexone based on trajectory-based reanalyses of two negative clinical trials

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4600601

The BRENDA model: integrating psychosocial treatment and pharmacotherapy for the treatment of alcohol use disorders

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4600601

Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4600601

Prolonged central mu-opioid receptor occupancy after single and repeated nalmefene dosing

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4600601

Effects of naltrexone and nalmefene on subjective response to alcohol among non-treatment-seeking alcoholics and social drinkers

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4600601

Pharmacotherapy of alcohol dependence: a review of the clinical data

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4600601

Barriers to the use of medications to treat alcoholism.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4600601

Efficacy of naltrexone and acamprosate for alcoholism treatment: a meta-analysis

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4600601

A double-blind, placebo-controlled study of oral nalmefene for alcohol dependence

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4600601

A double-blind, placebo-controlled pilot study to evaluate the efficacy and safety of oral nalmefene HCl for alcohol dependence

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4600601

Binding of a new opiate antagonist, nalmefene, to rat brain membranes.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4600601

A randomized, multicentre, open-label, comparative trial of disulfiram, naltrexone and acamprosate in the treatment of alcohol dependence

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4600601

Targeted use of naltrexone without prior detoxification in the treatment of alcohol dependence: a factorial double-blind, placebo-controlled trial

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4600601

Nalmefene causes greater hypothalamic-pituitary-adrenal axis activation than naloxone in normal volunteers: implications for the treatment of alcoholism

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4600601

Effects of liver disease on the disposition of the opioid antagonist nalmefene

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4600601

Nalmefene: intravenous safety and kinetics of a new opioid antagonist

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4600601

Nalmefene: safety and kinetics after single and multiple oral doses of a new opioid antagonist

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4600601

Predictors of compliance with naltrexone among alcoholics.

2 June 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0096-4

Extending the treatment options in alcohol dependence: a randomized controlled study of as-needed nalmefene

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0096-4

A randomised, double-blind, placebo-controlled, efficacy study of nalmefene, as-needed use, in patients with alcohol dependence.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0096-4

Differences in delta- and mu-opioid receptor blockade measured by positron emission tomography in naltrexone-treated recently abstinent alcohol-dependent subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0096-4

Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0096-4

Efficacy of Naltrexone and Acamprosate for Alcoholism Treatment: A Meta-Analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0096-4

Naltrexone depot for treatment of alcohol dependence: a multicenter, randomized, placebo-controlled clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0096-4

Correlation of stable elevations in striatal mu-opioid receptor availability in detoxified alcoholic patients with alcohol craving: a positron emission tomography study using carbon 11-labeled carfentanil

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0096-4

Brain opioid receptor binding in early abstinence from alcohol dependence and relationship to craving: an [11C]diprenorphine PET study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0096-4

A multi-site dose ranging study of nalmefene in the treatment of alcohol dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0096-4

A clinical laboratory paradigm for evaluating medication effects on alcohol consumption: naltrexone and nalmefene

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0096-4

Effect of nalmefene 20 and 80 mg on the corrected QT interval and T-wave morphology: a randomized, double-blind, parallel-group, placebo- and moxifloxacin-controlled, single-centre study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0096-4

Targeted naltrexone treatment moderates the relations between mood and drinking behavior among problem drinkers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0096-4

The effect of naltrexone on alcohol's stimulant properties and self-administration behavior in social drinkers: influence of gender and genotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0096-4

Predicting treatment response to naltrexone: the influence of craving and family history

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0096-4

Clinical predictors of response to naltrexone in alcoholic patients: who benefits most from treatment with naltrexone?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0096-4

Family history of alcoholism influences naltrexone-induced reduction in alcohol drinking.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0096-4

Predictors for the efficacy of naltrexone treatment in alcohol dependence: sweet preference.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0096-4

A functional polymorphism of the mu-opioid receptor gene is associated with naltrexone response in alcohol-dependent patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0096-4

Opioid antagonists for alcohol dependence

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4600601

Does family history of alcoholism moderate naltrexone's effects on alcohol use?

27 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4600601

Targeted naltrexone for early problem drinkers

27 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4600601

Binding affinity and selectivity of opioids at mu, delta and kappa receptors in monkey brain membranes.

27 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4600601

Targeted naltrexone treatment of early problem drinkers

27 November 2018

1 reference

12 December 2020

Targeted versus daily naltrexone: secondary analysis of effects on average daily drinking

1 reference

12 December 2020

Naltrexone and Cognitive Behavioral Coping Skills Therapy for the Treatment of Alcohol Drinking and Eating Disorder Features in Alcohol-Dependent Women: A Randomized Controlled Trial

1 reference

12 December 2020

Family history and antisocial traits moderate naltrexone's effects on heavy drinking in alcoholics

1 reference

12 December 2020

10.1007/S40263-013-0096-4

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23881605%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23881605%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

PubMed publication ID

23881605

1 reference